In propensity-matched adults with obesity, fracture risk over a mean follow-up of 3 years was lower with semaglutide than with sleeve gastrectomy (hazard ratio 0.74).
In plain wordsIn adults with obesity, people on semaglutide had fewer fractures over 3 years than people who had sleeve gastrectomy surgery.
- Peptide
- Semaglutide
- Outcome
- DecreaseFracture risk, semaglutide versus sleeve gastrectomy
- Study
n = 5,774
- Comparator
- Sleeve gastrectomy
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- Dose not stated
Measurements
- Hazard ratio
- 0.74 ratio
- semaglutide vs sleeve gastrectomy
- Fracture incidence
- 2.98%
- semaglutide
- Fracture incidence
- 4.43%
- sleeve gastrectomy
Source sentences
Over a mean follow-up of 3 years, the semaglutide group experienced 86 fractures (2.98%) compared to 128 (4.43%) in the SG group (hazard ratio 0.74, 95% confidence interval: 0.56-0.98; E-value: 1.2).
2 context sentences(design, population, supporting numbers)
This study aimed to compare fracture risk in patients with obesity treated with semaglutide or sleeve gastrectomy (SG) using a large, real-world electronic health record dataset.
After high-dimensional propensity score matching, there were 2887 individuals in each group.